The Radiochemist will manage the development and validation of manufacturing and QC procedures for clinical-stage radiopharmaceutical assets in compliance with GMP regulations. They will also support regulatory filings and ensure all documentation aligns with the company's quality management system.
The role involves driving sales performance and managing strategic accounts across Europe with a focus on hospital contracting and product promotion. You will build deep market insights and maintain strong relationships within the nuclear medicine and radiopharmaceutical community to meet business objectives.
Support the international roll-out of approved prostate cancer imaging agents. Advance the portfolio of late clinical-stage products addressing unmet needs in oncology and rare diseases.
The Medical Science Liaison will engage in scientific exchanges with medical experts to support Telix Pharmaceutical's products and research areas. They are responsible for identifying research gaps, supporting clinical trial recruitment, and executing field activities aligned with medical affairs strategies.
The Medical Science Liaison will engage in scientific exchange with medical experts to support Telix Pharmaceuticals' products and research areas. They are responsible for identifying research gaps, supporting clinical trial recruitment, and executing medical affairs strategies.
The Sr Director, Product Development Lead will oversee the global development of late-stage radiopharmaceutical compounds for therapeutic oncology indications. This role involves cross-functional leadership across clinical, regulatory, CMC, and commercial teams to drive program milestones and regulatory approvals.
The Director will lead the implementation and maturation of a global business resiliency management system, ensuring consistent capabilities across business continuity, crisis management, and emergency preparedness. They will partner with senior leadership to integrate resiliency into operations and drive organizational accountability for risk-based improvements.
